MedTrace Logo

A Phase II Clinical Study of QR12000 Compound Tablets in Patients With Moderate to Severe Essential Hypertension

NCT07700875 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 391

Last updated 2026-07-14

No results posted yet for this study

Summary

The purpose of this study is to compare the antihypertensive effect of QR12000 Compound Tablets with its single component, QR01019 potassium salt, and with valsartan in patients with moderate to severe essential hypertension.

Conditions

  • Essential Hypertension

Interventions

DRUG

QR01019 potassium salt 50 mg placebo

Matching placebo of QR01019 potassium salt 50 mg QD

DRUG

Sacubitril / valsartan 200 mg

Sacubitril / valsartan 200 mg QD

DRUG

Sacubitril / valsartan 200 mg placebo

Matching placebo of Sacubitril / valsartan 200 mg QD

DRUG

Valsartan 160 mg

Valsartan 160 mg QD

DRUG

Valsartan 160 mg placebo

Matching placebo of Valsartan 160mg QD

DRUG

QR12000 Compound Tablets 75 mg

QR12000 Compound Tablets 75 mg QD

DRUG

QR12000 Compound Tablets 75 mg placebo

Matching placebo of QR12000 Compound Tablets 75 mg QD

DRUG

QR12000 Compound Tablets 150 mg

QR12000 Compound Tablets 150 mg QD

DRUG

QR12000 Compound Tablets 150 mg placebo

Matching placebo of QR12000 Compound Tablets 150 mg QD

DRUG

QR01019 potassium salt 50 mg

QR01019 potassium salt 50 mg QD

Sponsors & Collaborators

  • Wuhan Createrna Science and Technology Co., Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-29
Primary Completion
2023-08-20
Completion
2023-09-11

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07700875 on ClinicalTrials.gov